Company: APXIF
Filing Date: 2025-03-31
Form Type: F-4/A
Source: 0001213900-25-026339
Chunk: 383

Company: APx Acquisition Corp. I
Filing Date: 2025-03-31
Form: F-4/A
Chunk 383
---
 conditions to deploy pilot testing in patients in Argentina. Oncology: Solid Tumor CGP (Comprehensive Genomic Profile) Through our exclusive Commercialization Agreement with CIBIC, who works on a shared project with F. Hoffmann -LaRoche AG (“Roche”), we are advancing a project to integrate a genomic profiling panel into routine diagnostics for solid tumors in Argentina. This project leverages Roche’s proprietary technology and the proven capabilities of the FoundationOne® CDx panel to provide comprehensive genomic insights from tissue samples. In Argentina, CIBIC will be responsible for providing the commercial channels and may provide supplies for processing samples in certain cases, while we will manage the technology implementation and develop result interpretation and support. Roche, in turn, will supply the necessary reagents and IT solutions. Successful project implementation in Argentina is expected to serve as a model for potential expansion into Roche’s network of clients within Latin America, specifically including Argentina, Uruguay, Paraguay, and Bolivia. As the project scales, we plan to assume responsibility for providing the commercial channels. Additionally, through CIBIC in Argentina, we collaborate with Roche Argentina and Hospital Austral on a clinical trial assessing the impact of liquid biopsies on altering treatment plans for patients with treatment -naïvemetastatic lung adenocarcinoma, a step that could significantly enhance personalized treatment options in precision oncology. 198 Oncology: Hereditary Cancer RNA test We plan to integrate RNA genetic testing into our hereditary cancer panel to provide more clinically actionable insights. Recognizing that many patients with a suspected genetic predisposition to cancer often receive inconclusive results from DNA -onlytesting, this project aims to provide specific results and significantly reduce uncertainty. By incorporating RNA testing with the DNA testing, we will enhance our ability to detect variants and interpret mutations which will allow for a more precise determination of pathogenicity, offering patients and their families more definitive and informative results. Polygenic Risk Scores: Breast Cancer, Cardiovascular Disease, Prostate Cancer, Type II Diabetes This initiative focuses on the evaluation and clinical application of PRS, which synthesize the risk across a vast array of genetic variants to assess an individual’s predisposition to common diseases. While PRS have shown enhanced predictive capabilities, making them increasingly relevant in clinical settings, their effective use raises questions, particularly concerning their applicability to diverse populations with different ethnicities and genetic backgrounds than those they were originally developed for. This project aims to assess the performance of various published PRS within our local demographic, examining their utility